Neurotensin as a marker and therapeutic target for sepsis
US8449864B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Oct 19, 2007 |
| Grant date | May 28, 2013 |
| Priority date | — |
| Expiry date | Apr 11, 2031 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/26
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Sepsis is a complex, incompletely understood and often fatal disorder, typically accompanied by hypotension, that is considered to represent a dysregulated host response to an infection. Neurotensin (NT) is 13-amino-acid peptide that, among its multiple effects, induces hypotension. It is shown herein that plasma concentrations of NT are increased in humans with sepsis and in mice after caecal ligation and puncture (CLP), a model of sepsis. Mast cells can degrade NT through neurotensin receptor 1-and neurolysin-dependent mechanisms, diminishing the hypotensive effects of NT, reducing intraperitoneal NT concentrations, and improving survival. These findings show that mast cells can regulate NT concentrations, and identify NT as a biomarker and therapeutic target in sepsis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.